Back to results

RecruitingPhase 3

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

NCT07205822

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Research Site

Largo, Florida, United States

+39 additional locations

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479 information.center@astrazeneca.com

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2025-10-30
Enrollment: 100 participants
Sponsor: AstraZeneca
Purpose: treatment

Locations (40)

Research SiteLargo, Florida, United States
Research SiteFort Wayne, Indiana, United States
Research SiteOmaha, Nebraska, United States
Research SiteNew York, New York, United States
Research SiteHouston, Texas, United States
Research SitePuyallup, Washington, United States
Research SiteBeijing, China
Research SiteChangsha, China
Research SiteGuangzhou, China
Research SiteLinyi, China
Research SiteShandong, China
Research SiteWuhan, China
Research SiteZhengzhou, China
Research SiteClermont-Ferrand, France
Research SiteLa Roche-sur-Yon, France
Research SiteMontpellier, France
Research SiteParis, France
Research SitePierre-Bénite, France
Research SiteAviano, Italy
Research SiteFlorence, Italy
Research SiteMeldola, Italy
Research SiteMilan, Italy
Research SiteNaples, Italy
Research SiteRoma, Italy
Research SiteBukgu, South Korea
Research SiteGoyang-si, South Korea
Research SiteSeoul, South Korea
Research SiteSeoul, South Korea
Research SiteSeoul, South Korea
Research SiteSeoul, South Korea
Research SiteSeoul, South Korea
Research SiteSeoul, South Korea
Research SiteSeoul, South Korea
Research SiteA Coruña, Spain
Research SiteBarcelona, Spain
Research SiteGranada, Spain
Research SiteMadrid, Spain
Research SiteMadrid, Spain
Research SiteSeville, Spain
Research SiteValencia, Spain